Cargando…

A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations

BACKGROUND: SUBLIVAC FIX Birch (SUB-B) is a liquid oral preparation of Betula verrucosa pollen extract for the treatment of allergic rhinitis/rhinoconjuctivitis induced by birch pollen. The major allergen content of SUB-B and Staloral Birch (Stal-B) have been shown to be comparable. In order to comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klimek, Ludger, Sperl, Annette, van Twuijver, Esther, van Ree, Ronald, Kleinjans, Huub, Boot, Johan Diderik, Pfaar, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122029/ https://www.ncbi.nlm.nih.gov/pubmed/25097754 http://dx.doi.org/10.1186/2045-7022-4-23

Ejemplares similares

A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study
por: Pfaar, O., et al.
Publicado: (2015)

Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial
por: Klimek, Ludger, et al.
Publicado: (2015)

Clinical endpoints in allergen immunotherapy: State of the art 2022
por: Gerth van Wijk, Roy, et al.
Publicado: (2023)

Digital health for allergen immunotherapy
por: Dramburg, Stephanie, et al.
Publicado: (2022)

Case Report: Safe and Effective Sublingual Birch Allergen Immunotherapy in Two HIV-Positive Patients
por: Latysheva, Elena, et al.
Publicado: (2021)

7 Comparison of Efficacy and Safety of a Dipigmented Polymerized Allergen Extract of Grass and Birch with Placebo in Patients With Type-1 Allergic Rhinoconjunctivitis
por: Sager, Angelika, et al.
Publicado: (2012)

A high‐dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio
por: Pfaar, Oliver, et al.
Publicado: (2023)

A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG(4) to allergens from all trees in the birch homologous group
por: Couroux, Peter, et al.
Publicado: (2018)

Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study
por: Pfaar, Oliver, et al.
Publicado: (2015)

Preparation of chemically stable allergen‐specific sublingual immunotherapy from Egyptian allergens
por: Abu El‐Enin, Mohammed A., et al.
Publicado: (2022)

Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
por: Blome, Christine, et al.
Publicado: (2020)

Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany
por: Brehler, Randolf, et al.
Publicado: (2016)

First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients
por: Bergmann, Karl-Christian, et al.
Publicado: (2020)

High Environmental Ozone Levels Lead to Enhanced Allergenicity of Birch Pollen
por: Beck, Isabelle, et al.
Publicado: (2013)

Allergen immunotherapy during the COVID‐19 pandemic—A survey of the German Society for Allergy and Clinical Immunology
por: Pfaar, Oliver, et al.
Publicado: (2022)

Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long‐term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis
por: Novak, Natalija, et al.
Publicado: (2022)

10 Seasonal Versus Symptom-based Evaluation of a Depigmented Grass-Birch Allergoid
por: Pfaar, Oliver, et al.
Publicado: (2012)

Variation in allergen content in sublingual allergen immunotherapy with house dust mites
por: Moreno Benítez, F., et al.
Publicado: (2015)

Long-term effects of allergen sublingual immunotherapy
por: Bozek, Andrzej, et al.
Publicado: (2019)

Adjuvanting Allergen Extracts for Sublingual Immunotherapy: Calcitriol Downregulates CXCL8 Production in Primary Sublingual Epithelial Cells
por: Pelst, Michael P., et al.
Publicado: (2020)

Nondaily dosing schedule of allergen-specific sublingual immunotherapy: efficacy and safety
por: Abdelwahab, Heba Wagih, et al.
Publicado: (2023)

Commentary: Sublingual Allergen Immunotherapy in HIV-Positive Patients
por: Chirumbolo, Salvatore
Publicado: (2016)

Comparative proteomics of common allergenic tree pollens of birch, alder, and hazel
por: Darnhofer, Barbara, et al.
Publicado: (2021)

The History and Science of the Major Birch Pollen Allergen Bet v 1
por: Breiteneder, Heimo, et al.
Publicado: (2023)

Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study
por: Worm, Margitta, et al.
Publicado: (2014)

Birch allergen challenges in allergic conjunctivitis using standard conjunctival allergen challenge and environmental exposure chamber
por: Gherasim, Alina, et al.
Publicado: (2021)

Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?
por: Pfaar, Oliver, et al.
Publicado: (2015)

Fold stability during endolysosomal acidification is a key factor for allergenicity and immunogenicity of the major birch pollen allergen
por: Machado, Yoan, et al.
Publicado: (2016)

High-Yield Production of the Major Birch Pollen Allergen Bet v 1 With Allergen Immunogenicity in Nicotiana benthamiana
por: Yamada, Yuki, et al.
Publicado: (2020)

The Major Birch Pollen Allergen Bet v 1 Induces Different Responses in Dendritic Cells of Birch Pollen Allergic and Healthy Individuals
por: Smole, Ursula, et al.
Publicado: (2015)

Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs
por: Pfaar, O., et al.
Publicado: (2020)

Placebo effects in allergen immunotherapy: an experts’ opinion
por: Frew, Anthony J., et al.
Publicado: (2018)

Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy
por: Pfaar, O., et al.
Publicado: (2020)

Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen
por: Aliu, Have, et al.
Publicado: (2017)

Sublingual allergen immunotherapy for respiratory allergy: a systematic review
por: Blanco, Carlos, et al.
Publicado: (2018)

Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy
por: Moral, Angel, et al.
Publicado: (2016)

Development of a novel method for identification and quantification of birch pollen allergens in parallel
por: Spiric, Jelena, et al.
Publicado: (2014)

Ligand Binding Modulates the Structural Dynamics and Compactness of the Major Birch Pollen Allergen
por: Grutsch, Sarina, et al.
Publicado: (2014)

Sublingual Immunotherapy: How Sublingual Allergen Administration Heals Allergic Diseases; Current Perspective about the Mode of Action
por: Gotoh, Minoru, et al.
Publicado: (2021)

Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollen‐allergic patients with apple allergy
por: Kinaciyan, T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jldjnh30g5indq7mpl2kq8tc5o